FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
ours per response	e 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																				
Name and Address of Reporting Person Hoenlein Malcolm				2. Issuer Name and Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner											
(Last) (First) (Middle) C/O FORTRESS BIOTECH, INC., 2 GANSEVOORT STREET, 9TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 08/26/2020							-	Office	er (give title belo	ow)	Other (specif	below	v)					
(Street) NEW YORK, NY 10014				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person										
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			Execution Date, if Cod		3. Transa Code (Instr. 8)				ed of	5. Amount of Se Beneficially Ow Reported Transa (Instr. 3 and 4)		ially Owned d Transactio	Following	6. Ownershi Form: Direct (D	p of Be	7. Nature of Indirect Beneficial Ownership						
				(ivion		<u> </u>	Code	V	Amou	(A)		rice	(mstr. 3	instr. 3 and 4)		` /		nstr. 4)				
	SERIES A CUMULATIVE PERPETUAL PREFERRED 08/26/2020 STOCK		08/26/2020			P			16,66	7 A	\$		16,667			D						
Reminder:	Report on a s	separate line for e	ach class of securit	erivati	ve Securi	ities	P c th	erso ontai ne fo	ns who	respo this fo plays a	orm a cur nefic	are i rrent	not requ lly valid	OMB con	formation spond unle trol numbe	ess	C 147	74 (9-02)				
1. Title of	l ₂	3. Transaction	3A. Deemed	.g., put	s, calls, v		ants, opti						e and	8. Price of	9. Number	of 10.		11 Notus				
Derivative Security	Conversion or Exercise Price of Derivative Security		Execution Date	C	ode	of De Se Ac (A Di of (Ir	ımber a	and Expiration Date (Month/Day/Year) A US (I		ation Date Am ay/Year) Und Sec		iration Date Day/Year) Am Unc Sec (Ins		ation Date Am Day/Year) Und Sec (Ins		Inder Jecuri Instr.	nt of lying		Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owne Form Deriva Securi Direct or Ind	of ative ty: (D) irect	11. Natur of Indirect Beneficia Ownersh (Instr. 4)
					Code V	(A		Date Exerci		Expiratio Date	On T	itle	Amount or Number of Shares									

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Hoenlein Malcolm C/O FORTRESS BIOTECH, INC. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X					

Signatures

/s/ Samuel W. Berry / Attorney in Fact	09/01/2020			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.